Novo Nordisk confirmed it is now seeking a successor for Jørgensen, but these are big shoes that need filling. As Novo notes, "during his eight-year tenure as CEO, Novo Nordisk's sales ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

COPENHAGEN (Reuters) - Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug ...

Novo Nordisk, the maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by "mutual agreement" with the company's board of directors, citing "recent market challenges ...

Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight-loss drugs. The Ozempic maker’s chief executive, ...

Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of leadership was required amid fierce glucagon-like peptide 1 receptor ...

Wegovy and Ozempic-maker Novo Nordisk said today its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity ...

You can reach Andrew on Signal at drewqjoseph.45. LONDON — Lars Fruergaard Jørgensen, who led Novo Nordisk as it rode the boom of its obesity and diabetes medications to become one of the ...

Novo said on Friday its current CEO will step down The obesity drug maker has struggled to compete against U.S. rival Eli Lilly American CEO may be better to deal with a Trump admin, analysts said ...

Investing.com -- Shares of Novo Nordisk (NYSE:NVO) fell 3% Friday after, in a surprise move, the company announced that CEO Lars Fruergaard Jørgensen will step down from his role. The company ...

Danish pharmaceutical giant Novo Nordisk's shares have more than halved in value since June last year amid intensifying competition in the obesity drug market. The CEO of Danish pharmaceutical ...